97 related articles for article (PubMed ID: 27258564)
21. Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type.
Sartori E; Langer R; Vassella E; Hewer E; Schucht P; Zlobec I; Berezowska S
Oncol Rep; 2017 Oct; 38(4):2394-2400. PubMed ID: 28765916
[TBL] [Abstract][Full Text] [Related]
22. IRX1 is a novel gene, overexpressed in high-grade IDH-mutant astrocytomas.
Sugur HS; Rao S; Sravya P; Athul Menon K; Arivazhagan A; Mehta B; Santosh V
Pathol Res Pract; 2023 May; 245():154464. PubMed ID: 37116364
[TBL] [Abstract][Full Text] [Related]
23. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
[TBL] [Abstract][Full Text] [Related]
24. IDH-1R132H mutation status in diffuse glioma patients: implications for classification.
Wang PF; Liu N; Song HW; Yao K; Jiang T; Li SW; Yan CX
Oncotarget; 2016 May; 7(21):31393-400. PubMed ID: 27120786
[TBL] [Abstract][Full Text] [Related]
25. A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
Xi S; Huang Q; Zeng J
J Neuropathol Exp Neurol; 2024 Jan; 83(2):125-130. PubMed ID: 38175671
[TBL] [Abstract][Full Text] [Related]
26. Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma.
Schittenhelm J; Mittelbronn M; Meyermann R; Melms A; Tatagiba M; Capper D
Acta Neuropathol; 2011 Nov; 122(5):651-2. PubMed ID: 21983902
[No Abstract] [Full Text] [Related]
27. Utility of real-time polymerase chain reaction for the assessment of CDKN2A homozygous deletion in adult-type IDH-mutant astrocytoma.
Shimizu Y; Suzuki M; Akiyama O; Ogino I; Matsushita Y; Satomi K; Yanagisawa S; Ohno M; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Kondo A
Brain Tumor Pathol; 2023 Apr; 40(2):93-100. PubMed ID: 36788155
[TBL] [Abstract][Full Text] [Related]
28. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.
Reis GF; Pekmezci M; Hansen HM; Rice T; Marshall RE; Molinaro AM; Phillips JJ; Vogel H; Wiencke JK; Wrensch MR; Walsh KM; Perry A
J Neuropathol Exp Neurol; 2015 May; 74(5):442-52. PubMed ID: 25853694
[TBL] [Abstract][Full Text] [Related]
29. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.
Gierke M; Sperveslage J; Schwab D; Beschorner R; Ebinger M; Schuhmann MU; Schittenhelm J
J Cancer Res Clin Oncol; 2016 Jan; 142(1):89-100. PubMed ID: 26115961
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
[TBL] [Abstract][Full Text] [Related]
31. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
[TBL] [Abstract][Full Text] [Related]
32. IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.
Darlix A; Deverdun J; Menjot de Champfleur N; Castan F; Zouaoui S; Rigau V; Fabbro M; Yordanova Y; Le Bars E; Bauchet L; Gozé C; Duffau H
J Neurooncol; 2017 May; 133(1):37-45. PubMed ID: 28434111
[TBL] [Abstract][Full Text] [Related]
33. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
[TBL] [Abstract][Full Text] [Related]
34. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
[TBL] [Abstract][Full Text] [Related]
35. Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.
Wang PF; Song HW; Cai HQ; Kong LW; Yao K; Jiang T; Li SW; Yan CX
Oncotarget; 2017 Jul; 8(30):50117-50123. PubMed ID: 28223536
[TBL] [Abstract][Full Text] [Related]
36. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma.
Kickingereder P; Sahm F; Radbruch A; Wick W; Heiland S; Deimling Av; Bendszus M; Wiestler B
Sci Rep; 2015 Nov; 5():16238. PubMed ID: 26538165
[TBL] [Abstract][Full Text] [Related]
37. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
38. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
39. Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-Wild-Type Diffuse Astrocytic Gliomas.
Ohka F; Shinjo K; Deguchi S; Matsui Y; Okuno Y; Katsushima K; Suzuki M; Kato A; Ogiso N; Yamamichi A; Aoki K; Suzuki H; Sato S; Arul Rayan N; Prabhakar S; Göke J; Shimamura T; Maruyama R; Takahashi S; Suzumura A; Kimura H; Wakabayashi T; Zong H; Natsume A; Kondo Y
Cancer Res; 2019 Oct; 79(19):4814-4827. PubMed ID: 31431463
[TBL] [Abstract][Full Text] [Related]
40. Improved grading of IDH-mutated astrocytic gliomas.
Pirozzi CJ; Yan H
Nat Rev Neurol; 2018 Jul; 14(7):383-384. PubMed ID: 29855600
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]